• Something wrong with this record ?

Calcium signaling affects migration and proliferation differently in individual cancer cells due to nifedipine treatment

B. Chovancova, V. Liskova, S. Miklikova, S. Hudecova, P. Babula, A. Penesova, A. Sevcikova, E. Durinikova, M. Novakova, M. Matuskova, O. Krizanova,

. 2020 ; 171 (-) : 113695. [pub] 20191109

Language English Country Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc20025286

Several papers have reported that calcium channel blocking drugs were associated with increased breast cancer risk and worsened prognosis. One of the most common signs of breast tumors is the presence of small deposits of calcium, known as microcalcifications. Therefore, we studied the effect of dihydropyridine nifedipine on selected calcium transport systems in MDA-MB-231 cells, originating from triple negative breast tumor and JIMT1 cells that represent a model of HER2-positive breast cancer, which possesses amplification of HER2 receptor, but cells do not response to HER2 inhibition treatment with trastuzumab. Also, we compared the effect of nifedipine on colorectal DLD1 and ovarian A2780 cancer cells. Both, inositol 1,4,5-trisphosphate receptor type 1 (IP3R1) and type 1 sodium calcium exchanger (NCX1) were upregulated due to nifedipine in DLD1 and A2780 cells, but not in breast cancer MDA-MB-231 and JIMT1 cells. On contrary to MDA-MB-231 and JIMT1 cells, in DLD1 and A2780 cells nifedipine induced apoptosis in a concentration-dependent manner. After NCX1 silencing and subsequent treatment with nifedipine, proliferation was decreased in MDA-MB-231, increased in DLD1 cells, and not changed in JIMT1 cells. Silencing of IP3R1 revealed increase in proliferation in DLD1 and JIMT1 cells, but caused decrease in proliferation in MDA-MB-231 cell line after nifedipine treatment. Interestingly, after nifedipine treatment migration was not significantly affected in any of tested cell lines after NCX1 silencing. Due to IP3R1 silencing, significant decrease in migration occurred in MDA-MB-231 cells after nifedipine treatment, but not in other tested cells. These results support different function of the NCX1 and IP3R1 in the invasiveness of various cancer cells due to nifedipine treatment.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20025286
003      
CZ-PrNML
005      
20201222153802.0
007      
ta
008      
201125s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.bcp.2019.113695 $2 doi
035    __
$a (PubMed)31706846
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Chovancova, Barbora $u Institute of Clinical and Translational Research, Biomedical Research Center SAS, Bratislava, Slovakia.
245    10
$a Calcium signaling affects migration and proliferation differently in individual cancer cells due to nifedipine treatment / $c B. Chovancova, V. Liskova, S. Miklikova, S. Hudecova, P. Babula, A. Penesova, A. Sevcikova, E. Durinikova, M. Novakova, M. Matuskova, O. Krizanova,
520    9_
$a Several papers have reported that calcium channel blocking drugs were associated with increased breast cancer risk and worsened prognosis. One of the most common signs of breast tumors is the presence of small deposits of calcium, known as microcalcifications. Therefore, we studied the effect of dihydropyridine nifedipine on selected calcium transport systems in MDA-MB-231 cells, originating from triple negative breast tumor and JIMT1 cells that represent a model of HER2-positive breast cancer, which possesses amplification of HER2 receptor, but cells do not response to HER2 inhibition treatment with trastuzumab. Also, we compared the effect of nifedipine on colorectal DLD1 and ovarian A2780 cancer cells. Both, inositol 1,4,5-trisphosphate receptor type 1 (IP3R1) and type 1 sodium calcium exchanger (NCX1) were upregulated due to nifedipine in DLD1 and A2780 cells, but not in breast cancer MDA-MB-231 and JIMT1 cells. On contrary to MDA-MB-231 and JIMT1 cells, in DLD1 and A2780 cells nifedipine induced apoptosis in a concentration-dependent manner. After NCX1 silencing and subsequent treatment with nifedipine, proliferation was decreased in MDA-MB-231, increased in DLD1 cells, and not changed in JIMT1 cells. Silencing of IP3R1 revealed increase in proliferation in DLD1 and JIMT1 cells, but caused decrease in proliferation in MDA-MB-231 cell line after nifedipine treatment. Interestingly, after nifedipine treatment migration was not significantly affected in any of tested cell lines after NCX1 silencing. Due to IP3R1 silencing, significant decrease in migration occurred in MDA-MB-231 cells after nifedipine treatment, but not in other tested cells. These results support different function of the NCX1 and IP3R1 in the invasiveness of various cancer cells due to nifedipine treatment.
650    _2
$a protinádorové látky imunologicky aktivní $x farmakologie $7 D000074322
650    _2
$a apoptóza $x účinky léků $x genetika $7 D017209
650    _2
$a nádory prsu $x genetika $x metabolismus $x patologie $7 D001943
650    _2
$a blokátory kalciových kanálů $x farmakologie $7 D002121
650    _2
$a vápníková signalizace $x účinky léků $x genetika $7 D020013
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a pohyb buněk $x účinky léků $x genetika $7 D002465
650    _2
$a proliferace buněk $x účinky léků $x genetika $7 D049109
650    _2
$a kolorektální nádory $x genetika $x metabolismus $x patologie $7 D015179
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a regulace genové exprese u nádorů $x účinky léků $7 D015972
650    _2
$a lidé $7 D006801
650    _2
$a inositol-1,4,5-trisfosfát - receptory $x genetika $x metabolismus $7 D053496
650    _2
$a nifedipin $x farmakologie $7 D009543
650    _2
$a nádory vaječníků $x genetika $x metabolismus $x patologie $7 D010051
650    _2
$a RNA interference $7 D034622
650    _2
$a receptor erbB-2 $x genetika $x metabolismus $7 D018719
650    _2
$a pumpa pro výměnu sodíku a vápníku $x genetika $x metabolismus $7 D019831
650    _2
$a trastuzumab $x farmakologie $7 D000068878
650    _2
$a triple-negativní karcinom prsu $x genetika $x metabolismus $x patologie $7 D064726
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Liskova, Veronika $u Institute of Clinical and Translational Research, Biomedical Research Center SAS, Bratislava, Slovakia.
700    1_
$a Miklikova, Svetlana $u Cancer Research Institute, Biomedical Research Center SAS, Bratislava, Slovakia.
700    1_
$a Hudecova, Sona $u Institute of Clinical and Translational Research, Biomedical Research Center SAS, Bratislava, Slovakia.
700    1_
$a Babula, Petr $u Department of Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic; International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic.
700    1_
$a Penesova, Adela $u Institute of Clinical and Translational Research, Biomedical Research Center SAS, Bratislava, Slovakia.
700    1_
$a Sevcikova, Angelika $u Institute of Clinical and Translational Research, Biomedical Research Center SAS, Bratislava, Slovakia; Department of Chemistry, Faculty of Natural Sciences, University of Ss. Cyril and Methodius, Trnava, Slovakia.
700    1_
$a Durinikova, Erika $u Cancer Research Institute, Biomedical Research Center SAS, Bratislava, Slovakia.
700    1_
$a Novakova, Marie $u Department of Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic; International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic.
700    1_
$a Matuskova, Miroslava $u Cancer Research Institute, Biomedical Research Center SAS, Bratislava, Slovakia.
700    1_
$a Krizanova, Olga $u Institute of Clinical and Translational Research, Biomedical Research Center SAS, Bratislava, Slovakia; Department of Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic. Electronic address: olga.krizanova@savba.sk.
773    0_
$w MED00000704 $t Biochemical pharmacology $x 1873-2968 $g Roč. 171, č. - (2020), s. 113695
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31706846 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201222153758 $b ABA008
999    __
$a ok $b bmc $g 1599431 $s 1115972
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 171 $c - $d 113695 $e 20191109 $i 1873-2968 $m Biochemical pharmacology $n Biochem Pharmacol $x MED00000704
LZP    __
$a Pubmed-20201125
Back

Find record

Citation metrics

Archiving options